[MASI] Masimo Corp. Thesis 2026: SET Pulse Oximetry Drives Healthcare Patient Monitoring Capital Return

Key Takeaways

• MASI FY2025 revenue ~$2.20-2.35B (+8-13% YoY) with adj. EPS ~$4.50-4.85 reflecting continued post-2024 ~$2.20-2.35B aggregate Healthcare revenue (~100% aggregate revenue mix; selected primary post-September 2025 ~$1B+ Sound United Consumer Audio divestiture creating selected pure-play Healthcare Patient Monitoring focus + selected various aggregate SET Pulse Oximetry + selected various aggregate Patient Monitoring + selected various aggregate Capnography + selected various aggregate Brain Monitoring + selected various aggregate Hospital Automation) under continued President + CEO Katie Szyman since November 2024 (~1-year tenure as Masimo CEO; selected post-November 2024 succeeded Joe Kiani Founder + CEO retirement + selected post-September 2025 Sound United Consumer Audio divestiture).
• SET Pulse Oximetry cycle (~$2.0+B+ Healthcare core): ~$2.0-2.15B SET Pulse Oximetry + Patient Monitoring revenue (~93%+ Healthcare revenue mix); selected primary Masimo SET (Signal Extraction Technology) Pulse Oximetry + selected various aggregate Rainbow SET + selected various aggregate Capnography + selected various aggregate Brain Monitoring + selected various aggregate Patient Monitoring; selected various aggregate ~+8-12% aggregate SET Pulse Oximetry + Patient Monitoring revenue growth + selected various aggregate ~50%+ aggregate global hospital pulse oximetry market share.
• Hospital Automation + Telehealth pipeline: ~$120-200M Hospital Automation + Telehealth + Other revenue (~7% Healthcare revenue mix); selected primary Masimo SafetyNet (cloud Patient Monitoring) + selected various aggregate Iris (hospital workflow + monitoring) + selected various aggregate Hospital Automation + Telehealth pipeline; selected various aggregate ~+15-20% aggregate Hospital Automation + Telehealth revenue growth.
• Capital return + balance sheet: ~$0 dividend (no dividend track post-2007 NASDAQ IPO); $200-300M aggregate FY2024-2025 buyback program ($100-200M aggregate FY2025); aggregate capital return ~$100-200M FY2025; net leverage ratio ~negligible (selected ~debt-free post-September 2025 Sound United divestiture proceeds); ~52-55M diluted shares; investment-grade Baa3/BBB- credit rating.
• FY2026 thesis catalysts: SET Pulse Oximetry cycle + Hospital Automation + Telehealth pipeline + selected post-September 2025 Sound United Consumer Audio divestiture pure-play Healthcare focus + selected post-November 2024 Katie Szyman CEO transformation + selected ~50%+ global hospital pulse oximetry market share + selected potential post-2027 dividend initiation consideration.

Company Background

Masimo Corp. (NASDAQ: MASI) is one of the largest US specialty Pulse Oximetry + Patient Monitoring companies, founded 1989 as Masimo Corporation by Joe Kiani in Irvine California (36-year heritage; selected pioneer Signal Extraction Technology (SET) Pulse Oximetry). Selected post-August 2007 NASDAQ IPO ($54M aggregate IPO proceeds August 2007); selected post-2007-2024 selected various aggregate ~$2B+ aggregate cumulative tuck-in M&A platform expansion (selected post-April 2022 ~$1.025B+ Sound United (Bowers & Wilkins + Denon + Polk Audio + Marantz + selected various) Consumer Audio acquisition + selected post-September 2025 ~$1B+ Sound United Consumer Audio divestiture creating selected pure-play Healthcare Patient Monitoring focus); selected post-November 2024 Katie Szyman CEO appointment (succeeded post-November 2024 Joe Kiani Founder + CEO retirement); HQ Irvine California; ~7,500-8,000+ employees globally.

MASI operates 1 primary business: Healthcare Patient Monitoring 100% revenue ($2.20-2.35B). SET Pulse Oximetry + Patient Monitoring revenue 93%+ Healthcare revenue mix ($2.0-2.15B; selected primary Masimo SET + Rainbow SET + Capnography + Brain Monitoring + Patient Monitoring) + Hospital Automation + Telehealth + Other revenue 7% Healthcare revenue mix ($120-200M; selected primary Masimo SafetyNet + Iris + selected various aggregate Hospital Automation + Telehealth pipeline). Geographic mix: US 55%+ revenue ($1.20-1.30B; selected primary US Healthcare Patient Monitoring) + Europe + Asia Pacific + selected various international 45% ($0.99-1.06B; selected primary EU + Asia Pacific Healthcare Patient Monitoring).

Capital return: ~$0 dividend (no dividend track post-2007 NASDAQ IPO); $200-300M aggregate FY2024-2025 buyback program ($100-200M aggregate FY2025); aggregate capital return ~$100-200M FY2025; net leverage ratio ~negligible (selected ~debt-free post-September 2025 Sound United divestiture proceeds); investment-grade Baa3/BBB- credit rating.

SET Pulse Oximetry Cycle (~$2.0+B+ Healthcare Core)

The SET Pulse Oximetry cycle is MASI's foundation thesis: ~$2.0-2.15B SET Pulse Oximetry + Patient Monitoring revenue (~93%+ Healthcare revenue mix) + selected primary Masimo SET (Signal Extraction Technology) Pulse Oximetry + selected various aggregate Rainbow SET + selected various aggregate Capnography + selected various aggregate Brain Monitoring + selected various aggregate Patient Monitoring + selected various aggregate ~+8-12% aggregate SET Pulse Oximetry + Patient Monitoring revenue growth + selected various aggregate ~50%+ aggregate global hospital pulse oximetry market share. Selected primary MASI Healthcare platform: ~50%+ aggregate global hospital pulse oximetry market share + selected various aggregate ~$2-3B aggregate global hospital pulse oximetry market + selected various aggregate Masimo SET differentiation vs aggregate Nellcor (Medtronic) + Philips legacy pulse oximetry.

FY2025 SET Pulse Oximetry dynamics ($2.0-2.15B aggregate SET Pulse Oximetry + Patient Monitoring revenue): selected continued post-2024 ~+8-12% aggregate SET Pulse Oximetry + Patient Monitoring revenue growth + ~$2.0-2.15B aggregate revenue + selected various aggregate ~50%+ aggregate global hospital pulse oximetry market share + selected various aggregate Masimo SET + Rainbow SET + Capnography + Brain Monitoring + Patient Monitoring. Selected post-2024 ~$0.30-0.45 incremental annual EPS contribution as SET Pulse Oximetry cycle drives incremental margin + Healthcare revenue.

FY2026 catalyst: continued SET Pulse Oximetry cycle + ~$0.30-0.45 incremental annual EPS contribution under continued President + CEO Katie Szyman leadership (~1-year tenure). Selected aggregate ~$2.15-2.30B aggregate SET Pulse Oximetry + Patient Monitoring revenue + selected various ~+8-12% aggregate SET Pulse Oximetry + Patient Monitoring revenue growth + selected various aggregate ~50%+ aggregate global hospital pulse oximetry market share. Risks: Medtronic (Nellcor) + Philips + GE Healthcare + Apple (selected post-2025 Apple Watch SET Pulse Oximetry settlement litigation) + selected various aggregate global Pulse Oximetry + Patient Monitoring + selected various aggregate competitive displacement + selected various aggregate Apple Watch SET Pulse Oximetry settlement considerations + post-2025 selected various aggregate Apple ITC import ban modification considerations.

Hospital Automation + Telehealth Pipeline

The Hospital Automation + Telehealth pipeline is MASI's primary growth thesis: ~$120-200M Hospital Automation + Telehealth + Other revenue (~7% Healthcare revenue mix) + selected primary Masimo SafetyNet (cloud Patient Monitoring) + selected various aggregate Iris (hospital workflow + monitoring) + selected various aggregate Hospital Automation + Telehealth pipeline + selected various aggregate ~+15-20% aggregate Hospital Automation + Telehealth revenue growth.

FY2025 Hospital Automation + Telehealth dynamics: ~$120-200M aggregate Hospital Automation + Telehealth + Other revenue + selected various aggregate ~+15-20% aggregate Hospital Automation + Telehealth revenue growth + selected various aggregate Masimo SafetyNet + Iris + Hospital Automation + Telehealth pipeline. Selected post-2024 ~$0.10-0.20 incremental annual EPS contribution as Hospital Automation + Telehealth pipeline drives incremental Healthcare revenue.

FY2026 catalyst: continued Hospital Automation + Telehealth pipeline + ~$0.10-0.20 incremental EPS contribution. Selected aggregate ~$140-240M aggregate Hospital Automation + Telehealth + Other revenue + selected various aggregate ~+15-20% aggregate Hospital Automation + Telehealth revenue growth + selected various aggregate Masimo SafetyNet + Iris + Hospital Automation + Telehealth pipeline. Risks: Medtronic + Philips + GE Healthcare + Becton Dickinson + selected various aggregate global Hospital Automation + Telehealth + selected various aggregate competitive displacement.

Capital Position + Balance Sheet

Capital position + balance sheet: ~$0 dividend (no dividend track post-2007 NASDAQ IPO) + $200-300M aggregate FY2024-2025 buyback program ($100-200M aggregate FY2025) + aggregate capital return ~$100-200M FY2025 + net leverage ratio ~negligible (selected ~debt-free post-September 2025 Sound United divestiture proceeds) + ~52-55M diluted shares + investment-grade Baa3/BBB- credit rating.

FY2026 catalyst: continued ~$100-200M aggregate annual buybacks + selected continued post-September 2025 Sound United divestiture proceeds + selected continued ~debt-free balance sheet + selected potential post-2027 dividend initiation consideration. Selected post-September 2025 ~$1B+ aggregate Sound United Consumer Audio divestiture creates selected pure-play Healthcare Patient Monitoring focus + selected continued ~debt-free balance sheet support continued capital return + R&D + tuck-in M&A capacity + acquisition optionality.

Key Core Metrics

• FY2025 revenue ~$2.20-2.35B (+8-13% YoY) vs $2.05B FY2024; adj. EPS ~$4.50-4.85
• 1 segment: Healthcare Patient Monitoring ~100% (post-September 2025 Sound United Consumer Audio divestiture pure-play)
• Healthcare revenue mix: SET Pulse Oximetry + Patient Monitoring ~93%+ ($2.0-2.15B) + Hospital Automation + Telehealth + Other ~7% ($120-200M)
• Geographic mix: US ~55%+ + Europe + Asia Pacific + selected various international ~45%
• ~50%+ aggregate global hospital pulse oximetry market share
• ~52-55M diluted shares; ~$100-200M total capital return FY2025
• ~$0 dividend (no dividend track post-2007 NASDAQ IPO)
• $200-300M aggregate FY2024-2025 buyback program ($100-200M aggregate FY2025)
• Net leverage ratio ~negligible (~debt-free post-September 2025 Sound United divestiture)
• Investment-grade Baa3/BBB- credit rating
• President + CEO Katie Szyman (since November 2024, ~1-year tenure); CFO Micah Young
• Selected post-November 2024 Joe Kiani Founder + CEO retirement; selected post-September 2025 Sound United Consumer Audio divestiture pure-play Healthcare focus

Market Evaluation

MASI trades as a US specialty Pulse Oximetry + Patient Monitoring company levered to SET Pulse Oximetry cycle (~$2.0+B+ Healthcare core) + Hospital Automation + Telehealth pipeline + selected post-September 2025 Sound United Consumer Audio divestiture pure-play Healthcare focus. Bull case: ~$2.0-2.15B SET Pulse Oximetry + Patient Monitoring + ~$120-200M Hospital Automation + Telehealth + Other + ~50%+ aggregate global hospital pulse oximetry market share + selected post-September 2025 Sound United divestiture pure-play Healthcare focus + selected post-November 2024 Katie Szyman CEO + selected ~debt-free balance sheet drive ~$4.85-5.30 adj. EPS FY2026 (+5-10% YoY). Bear case: Medtronic (Nellcor) + Philips + GE Healthcare + Apple (Apple Watch SET Pulse Oximetry settlement) + Becton Dickinson competitive displacement + selected various aggregate Apple Watch SET Pulse Oximetry settlement considerations + selected post-2025 selected various aggregate Apple ITC import ban modification considerations + selected post-November 2024 Katie Szyman CEO transition continuity considerations + selected post-September 2025 Sound United divestiture closing considerations trigger material EPS compression. Base case: SET Pulse Oximetry cycle + Hospital Automation + Telehealth pipeline + selected post-September 2025 Sound United pure-play Healthcare focus + ~debt-free balance sheet support continued ~$4.85-5.30 adj. EPS + ~$100-200M aggregate capital return FY2026.

SET Pulse Oximetry Drives Healthcare Patient Monitoring Capital Return Deep Dive

Selected continued post-2024 ~$2.0-2.15B aggregate SET Pulse Oximetry + Patient Monitoring revenue (~93%+ Healthcare revenue mix; selected primary Masimo SET (Signal Extraction Technology) Pulse Oximetry + selected various aggregate Rainbow SET + selected various aggregate Capnography + selected various aggregate Brain Monitoring + selected various aggregate Patient Monitoring) + selected continued post-2024 ~$120-200M aggregate Hospital Automation + Telehealth + Other revenue (~7% Healthcare revenue mix; selected primary Masimo SafetyNet (cloud Patient Monitoring) + Iris (hospital workflow) + Hospital Automation + Telehealth pipeline) + selected continued post-2024 ~+8-12% aggregate SET Pulse Oximetry + Patient Monitoring revenue growth + selected continued post-2024 ~50%+ aggregate global hospital pulse oximetry market share + selected continued post-2024 selected primary Masimo SET differentiation vs aggregate Nellcor (Medtronic) + Philips legacy pulse oximetry + selected continued post-September 2025 ~$1B+ aggregate Sound United Consumer Audio divestiture creating selected pure-play Healthcare Patient Monitoring focus + selected continued post-November 2024 Joe Kiani Founder + CEO retirement + post-November 2024 Katie Szyman CEO appointment + selected ~$0 dividend (no dividend track post-2007 NASDAQ IPO) + selected ~$100-200M aggregate annual buybacks + selected ~debt-free balance sheet (post-September 2025 Sound United divestiture proceeds) + investment-grade Baa3/BBB- credit rating drive MASI's primary FY2026 thesis. President + CEO Katie Szyman (~1-year tenure) leadership continues post-November 2024 CEO appointment focus on SET Pulse Oximetry cycle + Hospital Automation + Telehealth pipeline + selected post-September 2025 Sound United Consumer Audio divestiture pure-play Healthcare focus + selected continued post-November 2024 Joe Kiani Founder + CEO retirement transition. Risks: Medtronic (Nellcor) + Philips + GE Healthcare + Apple (selected post-2025 Apple Watch SET Pulse Oximetry settlement litigation) + Becton Dickinson + selected various aggregate global Pulse Oximetry + Patient Monitoring + Hospital Automation + Telehealth + selected various aggregate competitive displacement + selected various aggregate Apple Watch SET Pulse Oximetry settlement considerations + post-2025 selected various aggregate Apple ITC import ban modification considerations + selected post-November 2024 Katie Szyman CEO transition continuity considerations + selected post-September 2025 Sound United Consumer Audio divestiture closing considerations + selected post-1989 Joe Kiani Founder + CEO retirement legacy + selected post-2007 NASDAQ IPO continuity considerations.